130P Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
- Resource Type
- Abstract
- Source
- In
Annals of Oncology October 2023 34 Supplement 2:S231-S232 - Subject
- Language
- ISSN
- 0923-7534